胆系肿瘤术后辅助治疗进展  

Progress on Postoperative Adjuvant Therapy for Biliary Tract Cancer

作　　者：卢珂 刘鲁迎 LU ke;LIU Lu-ying(Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Cancer and Basic Medicine,Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]中国科学院大学附属肿瘤医院(浙江省肿瘤医院),中国科学院肿瘤与基础医学研究所,浙江杭州310022

出　　处：《中国肿瘤》2020年第7期537-543,共7页China Cancer

摘　　要：胆系恶性肿瘤主要包括胆囊癌及胆管癌,在亚洲国家较为常见。胆系恶性肿瘤的预后很差,手术是唯一可能治愈的治疗方法,但术后复发转移比例高。在过去的几十年中,我们对这一类恶性肿瘤的分子生物学有了一定的了解,诊断技术也有了很大的发展,但术后辅助治疗一直没有明确的方案。该文拟就胆系恶性肿瘤的术后辅助化疗、辅助放化疗和预后因素等问题,综述其现状和研究进展,并讨论未来的治疗策略。Biliary tract cancer(BTC)including gallbladder carcinoma(GBC)and cholangiocarcinoma(CCA),is more common in Asian countries.Surgery is the only potentially curative treatment for BTC,but postoperative recurrence and metastasis rate is high,and the prognosis is unfavorable.In the past few decades,there has been more knowledge on the molecular biology of this malignancy and the diagnostic techniques are improved,however,there are still no standard protocols for adjuvant therapy.This article intends to review the status quo and research progress of BTC in terms of adjuvant chemotherapy,adjuvant chemoradiotherapy and prognostic factors for postoperative patients,and to discuss future treatment strategies.

关 键 词：胆系恶性肿瘤 辅助化疗 辅助放化疗 预后 

分 类 号：R735.8[医药卫生—肿瘤]